Research programme: SCAP ligands - GlaxoSmithKlineAlternative Names: GW 300; GW 532; GW 575; GW 707
Latest Information Update: 19 Mar 2007
At a glance
- Originator GlaxoSmithKline
- Mechanism of Action LDL receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 13 Feb 2002 New profile
- 13 Feb 2002 Preclinical development for Hyperlipidaemia in France (unspecified route)